Personalis, Inc. Files 8-K for Material Definitive Agreement

TL;DR

PSNL signed a big deal, details TBD.

AI Summary

On June 21, 2024, Personalis, Inc. entered into a Material Definitive Agreement. The filing does not provide specific details about the agreement or any associated financial figures. The company is incorporated in Delaware and headquartered in Fremont, California.

Why It Matters

This filing indicates a significant new contract or partnership for Personalis, Inc., which could impact its future revenue and operations.

Risk Assessment

Risk Level: medium — The lack of specific details in the 8-K regarding the material definitive agreement introduces uncertainty about its implications.

Key Players & Entities

• Personalis, Inc. (company) — Registrant
• June 21, 2024 (date) — Date of earliest event reported
• Delaware (jurisdiction) — State of Incorporation
• Fremont, California (location) — Principal Executive Offices
• 650-752-1300 (phone_number) — Registrant's Telephone Number

FAQ

Key Financial Figures

• $0.0001 — nge on which registered Common Stock, $0.0001 par value per share PSNL The Nasdaq

Filing Documents

• psnl-20240621.htm (8-K) — 48KB
• psnl-ex10_1.htm (EX-10.1) — 175KB
• 0000950170-24-078618.txt ( ) — 365KB
• psnl-20240621.xsd (EX-101.SCH) — 29KB
• psnl-20240621_htm.xml (XML) — 4KB

01 Entry into a Material Definitive Agreement

Item 1.01 Entry into a Material Definitive Agreement. On June 21, 2024 (the "Effective Date"), Personalis, Inc. (the "Company") and Foresight Diagnostics, Inc. ("Foresight") entered into a Settlement and License Agreement (the "S&L Agreement") pursuant to which the Company and Foresight agreed to settle certain previously disclosed litigation pending in U.S. federal district court (the "Litigation") and inter-partes review proceedings (the "IPRs") pending before the U.S. Patent Trial and Appeal Board (the "PTAB") in each case related to certain patents of the Company. Pursuant to the S&L Agreement, Foresight and the Company agreed to stipulate to dismiss pending claims of infringement and related defenses and counterclaims in the Litigation and request authorization from the PTAB to request termination of the IPRs and the Company granted Foresight a non-exclusive, worldwide license under certain patents of the Company to develop, manufacture, commercialize and otherwise exploit products and services that use whole genome sequencing and a variable content minimal/molecular residual disease panel that utilizes phased variants in consideration for which Foresight agrees to pay the Company a low-single digit tiered royalty on net sales of products and services covered by patents licensed by Company, subject to customary reductions. The license is perpetual and irrevocable, except in certain limited circumstances, which apply on a patent-by-patent basis. Upon the occurrence of certain specified change of control events involving specified parties with respect to Foresight, the highest percentage of the royalty tiers is subject to a very low single digit increase and Foresight will pay to Company a one-time fee in the low single-digit millions. Foresight and the Company also agreed, pursuant to the S&L Agreement, for each to release the other party from certain claims related to the Litigation, the IPRs, the licensed patents and the licensed products and services, and

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit Number Description 10.1*# Settlement and License Agreement, between Personalis, Inc. and Foresight Diagnostics, Inc., dated June 21, 2024. 104 Cover Page Interactive Data File (embedded within the inline XBRL document). * Pursuant to Item 601(a)(5) of Regulation S-K promulgated by the SEC, certain schedules and attachments to this exhibit have been omitted because they do not contain information material to an investment or voting decision and that information is not otherwise disclosed in the exhibit. # Pursuant to Item 601(b)(10)(iv) of Regulation S-K promulgated by the SEC, certain portions of this exhibit have been redacted because the Company customarily and actually treats such omitted information as private or confidential and because such omitted information is not material.

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Date: June 27, 2024 Personalis, Inc. By: /s/ Aaron Tachibana Aaron Tachibana Chief Financial Officer and Chief Operating Officer

View Full Filing

View this 8-K filing on SEC EDGAR